59/100B29.390
USD
-0.49
(-1.64%)
Post Trading·29.320USD-0.070(-0.24%)
Last updated: · Delayed 15 min
Fair valueNot reliable
Q4 FY2026 · Earnings report
EPS estimate 0.72Revenue estimate 17.14B
Q4 FY2026 · Earnings report
EPS estimate 0.72Revenue estimate 17.14B
Pfizer financials
Yes. Pfizer earned 4.03B USD of net income over the last twelve months, 6.3% of its revenue. It made a profit in 41 of its 41 fiscal years since 1985.
- Revenue (TTM)
- 63.62B USD
- Net income (TTM)
- 4.03B USD
- Free cash flow (TTM)
- 11.79B USD
- Cash and short-term investments
- 14.27B USD
- Total debt
- 62.67B USD
- Shareholders' equity
- 89.00B USD
Cash, debt and equity as of 27 Sept 2026.
Pfizer earnings
Next earnings · Q4 FY2026
EPS estimate
0.72 USD
Revenue estimate
17.14B USD
Last quarter · Q3 FY2026
EPS0.87Beat +18.4%Revenue16.58BBeat +4.6%
Revenue
ReportedEstimate
EPS
ReportedEstimate
| Period | Report date | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|---|
| Q3 FY2027 | 0.75 | — | — | -14.02% | 15.45B | — | — | -6.82% | |
| Q2 FY2027 | 0.66 | — | — | -14.77% | 14.49B | — | — | -3.62% | |
| Q1 FY2027 | 0.69 | — | — | -8.33% | 14.09B | — | — | -2.51% | |
| Q4 FY2026 | 0.72 | — | — | +9.09% | 17.14B | — | — | -2.37% | |
| Q3 FY2026 | 0.74 | 0.87 | +18.37% | 0.00% | 15.85B | 16.58B | +4.61% | -0.43% | |
| Q2 FY2026 | 0.68 | 0.77 | +12.90% | -1.28% | 14.40B | 15.03B | +4.41% | +2.60% | |
| Q1 FY2026 | 0.72 | 0.75 | +3.88% | -18.48% | 13.84B | 14.45B | +4.41% | +5.37% | |
| Q4 FY2025 | 0.57 | 0.66 | +16.40% | +4.76% | 16.85B | 17.56B | +4.20% | -1.16% | |
| Q3 FY2025 | 0.63 | 0.87 | +37.44% | -17.92% | 16.50B | 16.65B | +0.94% | -5.92% | |
| Q2 FY2025 | 0.58 | 0.78 | +34.48% | +30.00% | 13.56B | 14.65B | +8.06% | +10.31% |
| Period | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|
| FY2028 | 2.46 | — | — | -15.51% | 55.13B | — | — | -8.74% |
| FY2027 | 2.92 | — | — | -3.11% | 60.41B | — | — | -3.81% |
| FY2026 | 3.01 | — | — | -6.85% | 62.80B | — | — | +0.35% |
| FY2025 | 3.12 | 3.23 | +3.54% | +3.86% | 61.94B | 62.58B | +1.04% | -1.65% |
| FY2024 | 2.93 | 3.11 | +6.28% | +69.95% | 63.08B | 63.63B | +0.86% | +8.77% |
| FY2023 | 1.55 | 1.83 | +18.29% | -72.40% | 58.78B | 58.50B | -0.48% | -41.70% |
| FY2022 | 6.50 | 6.63 | +1.96% | +50.00% | 100.34B | 100.33B | -0.01% | +23.24% |
Pfizer growth and profitability
Full income statement- Revenue (TTM)
- 63.62B USD
- Net income (TTM)
- 4.03B USD
- Gross margin
- 73.37%
- Operating margin
- 23.83%
- Net margin
- 6.34%
Revenue / Net income
Revenue Net income Net margin
How Pfizer makes its money
Biopharma61.20B 97.8%
Segment Reporting, Reconciling Item, Corporate Nonsegment1.38B 2.2%
Revenue62.58B 100.0%
Cost of revenue16.07B 25.7%
Gross profit46.51B 74.3%
Research and development10.44B 16.7%
Selling and administration13.79B 22.0%
Other operating expenses4.87B 7.8%
Operating income17.41B 27.8%
Other expense9.90B 15.8%
Net income7.77B 12.4%
FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.
FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.
Pfizer revenue breakdown
By product
FY2025
97.8%Biopharma2.2%Segment Reporting, Reconciling Item, Corporate Nonsegment
| Segment | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| Biopharma | 61.20B | 97.8% | -1.9% |
| Segment Reporting, Reconciling Item, Corporate Nonsegment | 1.38B | 2.2% | — |
By region
FY2025
59.2%United States25.9%Developed Rest Of World14.9%Emerging Markets
| Region | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| United States | 37.08B | 59.2% | -4.2% |
| Developed Rest Of World | 16.19B | 25.9% | +0.8% |
| Emerging Markets | 9.31B | 14.9% | +4.9% |
Operating and free cash flow
Full cash flow statementOperating cash flow Free cash flow
Pfizer financial health
Full balance sheet- Cash and short-term investments
- 14.27B USD
- Total debt
- 62.67B USD
- Net cash
- -48.40B USD
- Free cash flow (TTM)
- 11.79B USD
- Current ratio
- 1.42
- Debt to equity
- 0.70
- Piotroski score
- 7 / 9
- Altman Z-score
- 2.19
Cash, debt and free cash flow
Cash and short-term investments Total debt Free cash flow
Assets, liabilities and equity
Total assets Total liabilities Shareholders' equity
Pfizer valuation
- Price to earnings ratio (TTM)
- 41.58
- Forward P/E (FY2026)
- 9.77
- Price to sales (TTM)
- 2.63
- Price to book
- 1.88
- EV / EBITDA (TTM)
- 16.03
Capital structure
Market capitalization
167.51B USD
+
Total debt
62.67B USD
−
Cash and short-term investments
14.27B USD
=
Enterprise value
215.91B USD
Valuation over time
P/EForward P/EForward P/E · EstimateEstimate
Pfizer against its own history
Each figure in the latest fiscal year against the same figure from FY2021 to FY2025: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.
Its peers: Gilead Sciences, Bristol-Myers Squibb, Amgen, Merck & Co., AbbVie, and Johnson & Johnson, the US Drug Manufacturers - General companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.
- P/E (today)Above its median41.66.875.5
- Gross marginHighest in 5 years74.3%58.1%74.3%Against its peers: 2 of 7Peers' median 70.9%
- Operating marginAbove its median27.8%7.4%37.7%Against its peers: 6 of 7Peers' median 31.0%
- Net marginBelow its median12.4%3.6%31.0%Against its peers: 6 of 7Peers' median 24.6%
- Return on equityBelow its median9.0%2.4%32.8%Against its peers: 6 of 6Peers' median 37.5%
- Free cash flow marginBelow its median14.5%8.0%36.7%Against its peers: 7 of 7Peers' median 24.3%
- Revenue growthBelow its median-1.6%-41.1%95.2%Against its peers: 7 of 7Peers' median 4.2%
- EPS growthBelow its median-3.5%-93.2%279.8%Against its peers: 6 of 6Peers' median 88.2%
- Debt to EBITDAAbove its median4.02×0.85×7.41×Against its peers: 7 of 7Peers' median 2.47×
- Current ratioBelow its median1.160.911.40Against its peers: 4 of 7Peers' median 1.20
Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.
Pfizer dividends
- Annual dividend
- 1.72 USD
- Dividend yield (indicated)
- 5.85%
- Payout ratio
- 243.35%
- Years of dividend growth
- 15
- Frequency
- Quarterly
- Last payment
- 0.43 USD
- Last ex-dividend date
- 6 Nov 2026
- Last payment date
- 7 Dec 2026
Dividends per share
Pfizer ownership
- Institutions
- 67.94%
- Institutional holders
- 2,965 (-132)
- Free float
- 99.91%
Who owns the shares
Institutions 67.9% Others 32.1%
As of 30 Jun 2026
Shares free to trade
Free float 5.69B shares ·99.9% Closely held 4.87M shares ·0.1%
Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.
Insider trading
| Quarter | Purchases | Sales | Shares acquired | Shares disposed of |
|---|---|---|---|---|
| Q4 2026 | 0 | 0 | 111.00 | 0.00 |
| Q3 2026 | 3 | 1 | 123.98K | 3.28K |
| Q2 2026 | 0 | 1 | 96.10K | 2.00K |
| Q1 2026 | 0 | 0 | 3.27M | 1.57M |
Shares outstanding
Basic shares Diluted shares Change in diluted shares
Common questions about Pfizer's financials
Source: Financial Modeling Prep